Qiagen N.v. · NYSE:QGEN

Qiagen — Exane BNPP DILS CEO Conference 2021

31 slides from Qiagen's conference presentation, Mar 5, 2021

1. Slide 1: Investor Presentation Q1 2021

   Investor Presentation Q1 2021 Thierry Bernard Chief Executive Officer Sample to Insight

2. Slide 2: Forward looking and intended use statements

   Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking competitors' products; market acceptance of QIAGEN's new products and the integration of statements. All statements other than statements of historical fact are, or may b

3. Slide 3: Overview

   Overview 1 Q4 2020: Exceeded sales and adjusted diluted EPS outlook Net sales Adjusted EPS(1) • $571 m net sales (+38% actual, +36% CER vs. ≥32% CER outlook) (In $ millions, at actual rates) (In $ per share) • $0.68 adj. diluted EPS ($0.68 CER vs. ~$0.64-0.65 CER outlook) +23% CER +52% CER • 34.4% a

4. Slide 4: Q4 and FY 2020: Financial review

   Q4 and FY 2020: Financial review Q4 Full year (In $ millions, unless indicated) (Diluted EPS in $ per share) 2020 2019 Change 2020 2019 Change Net sales(1) 571.2 413.5 38% / 36% CER 1,870.3 1,526.4 23% / 23% CER Operating income (loss) 155.9 80.0 95% 386.4 (26.1) NM Adjusted operating income 196.5 1

5. Slide 5: Sales by product groups

   Sales by product groups Q4 2020 net sales FY 2020 net sales Sales % change % CER Sales % change % CER Product group (in $ m) change (in $ m) change Sample technologies $236 59% 55% $804 47% 47% Diagnostic solutions(1) $159 37% 36% $461 -1% -1% Of which QuantiFERON $58 -1% -3% $190 -21% -21% Of which

6. Slide 6: Sales by product type and customer classes

   Sales by product type and customer classes Q4 2020 net sales FY 2020 net sales Sales % % CER % Sales % % CER % Product type (in $ m) change change of sales (in $ m) change change of sales Consumables and related revenues $494 36% 33% 86% $1,615 19% 20% 86% Instruments $77 57% 52% 14% $255 48% 48% 14

7. Slide 7: Sales by geographic regions

   Sales by geographic regions Q4 2020 net sales FY 2020 net sales Sales % % CER % Sales % % CER % Sales by geographic region (in $ m) change change of sales (in $ m) change change of sales Americas $247 38% 38% 43% $825 14% 15% 44% Europe / Middle East / Africa $225 54% 48% 40% $682 40% 39% 37% Asia-P

8. Slide 8: Sales by non-COVID-19 and COVID product groups

   Sales by non-COVID-19 and COVID product groups Q4 2020 net sales FY 2020 net sales Sales % % CER % Sales % % CER % (in $ m) change change of sales (in $ m) change change of sales Non-COVID-19 products $371 0% -2% 65% $1,252 -9% -9% 67% COVID-19 related products $200 389% 379% 35% $618 331% 332% 33%

9. Slide 9: 2020: Delivering on pandemic needs while aligning QIAGEN on 5 pillars of growth

   2020: Delivering on pandemic needs while aligning QIAGEN on 5 pillars of growth Meaningful COVID-19 sales impact Key achievements during an unprecedented year of change 2020 net sales (In $ millions, at actual rates) Aligned QIAGEN on 5 pillars of growth to drive mid-term expansion +23% CER $1,870 S

10. Slide 10: COVID-19 testing solutions: Serving evolving demand trends as pandemic progresses

    COVID-19 testing solutions: Serving evolving demand trends as pandemic progresses Capacity Q4 2020 sales: Updates status COVID-19 product groups Sample technologies • Reduced demand for manual kits more than offset by continuous increase in capacity for automated ~21% • QIAprep&amp being sold to man

11. Slide 11: 2021: Set to serve pandemic needs and further build out base for robust business

    2021: Set to serve pandemic needs and further build out base for robust business COVID-19 testing trends Non-COVID product trends • Single-plex PCR and rapid tests • Return of oncology and disease testing • Multi-plex and syndromic testing • Research labs reopening as lockdowns and restrictions ease

12. Slide 12: 2021 and beyond: Capturing opportunities in dynamic markets

    2021 and beyond: Capturing opportunities in dynamic markets FY 2021 (expected sales) Key drivers • Build on QIAsymphony cumulative placements from >2,900 at >$750 million end-2020 with 200 new placements in 2021 Sample technologies (Includes ~$60 m decrease in manual RNA sample prep sales) • Extend

13. Slide 13: Appointment of new Supervisory Board member

    Appointment of new Supervisory Board member Further complements and enhances the Board’s already Supervisory Board extensive experience in Life Sciences and Diagnostics Lawrence A. Rosen Toralf Haag Chair • CEO and Chairman of the Corporate Board of Management since 2019 of Voith GmbH & Co. KGaA wit

14. Slide 14: Q1 and FY 2021: Outlook and assumptions

    Q1 and FY 2021: Outlook and assumptions (As of February 9, 2020) Q1 2021 outlook FY 2021 outlook ≥+45% CER ~+18-20% CER Net sales (Prior year: $372.1 m) (Prior year: $1,870.3 m) ~$0.60-0.62 CER ~$2.42-2.46 CER Adjusted EPS(1) (Prior year: $0.34) (Prior year: $2.15) Adjustments to operating income (i

15. Slide 15: Summary

    Summary 1 Excellent Q4 and FY 2020 results: sales growth and adjusted diluted EPS exceed targets 2 Higher sequential non-COVID and COVID sales in Q4 2020 vs. Q2 and Q3 2020 3 Answering new challenges to pandemic response while managing post-COVID growth 4 Reaffirming 2021 outlook: ~+18-20% CER sales

16. Slide 16: Appendix

    A 1 | Appendix QIAGEN

17. Slide 17: QIAGEN sales reporting in new product groups

    QIAGEN sales reporting in new product groups Five pillars of growth Sample QIAcuity QIAstat-Dx NeuMoDx QuantiFERON QIAGEN product groups technologies(1) digital PCR(3) Consumables and instruments used in sample collection, stabilization, storage, Sample technologies(1) purification and quality contr

18. Slide 18: 2020: Quarterly sales by product groups

    2020: Quarterly sales by product groups Net sales by product group Q1 2020 Q2 2020 Q3 2020 Q4 2020 FY 2020 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 154 22% 24% 200 46% 49% 214 57% 56%

19. Slide 19: 2019: Quarterly sales by product groups

    2019: Quarterly sales by product groups Net sales by product group Q1 2019 Q2 2019 Q3 2019 Q4 2019 FY 2019 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 127 -3% 1% 137 1% 5% 136 3% 5% 148 0

20. Slide 20: 2020: Quarterly sales by customer class and region

    2020: Quarterly sales by customer class and region Net sales by customer class (In $ millions at actual rates / Q1 2020 Q2 2020 Q3 2020 Q4 2020 FY 2020 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Molecular Diagnostics 176 4% 7% 204 9% 12% 2

21. Slide 21: 2019: Quarterly sales by customer class and region

    2019: Quarterly sales by customer class and region Net sales by customer class (In $ millions at actual rates / Q1 2019 Q2 2019 Q3 2019 Q4 2019 FY 2019 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Molecular Diagnostics 168 4% 10% 188 1% 5% 1

22. Slide 22: Q4 2020: Consolidated Statements of Income (unaudited)

    Q4 2020: Consolidated Statements of Income (unaudited) Three months ended Three months ended (In $ thousands, except share data) December 31, 2020 December 31, 2019 Net sales 571,234 413,472 Cost of sales: Cost of sales 180,383 117,698 Acquisition-related intangible amortization 17,418 16,209 Total

23. Slide 23: FY 2020: Consolidated Statements of Income (unaudited)

    FY 2020: Consolidated Statements of Income (unaudited) Twelve months ended Twelve months ended (In $ thousands, except share data) December 31, 2020 December 31, 2019 Net sales 1,870,346 1,526,424 Cost of sales: Cost of sales 574,467 449,651 Acquisition-related intangible amortization 63,164 71,511

24. Slide 24: Q4 and FY 2020: Reconciliation adjusted results

    Q4 and FY 2020: Reconciliation adjusted results Net Gross Operating Pretax Income Tax Net Diluted In $ millions (Except EPS) profit income income tax rate income EPS (Unaudited) sales Fourth quarter 2020 Reported results 571.2 373.4 155.9 256.5 (43.8) 17% 212.7 0.91 Adjustments Business integration,

25. Slide 25: Q4 and FY 2020: Currency impact

    Q4 and FY 2020: Currency impact Net sales Net sales Currency exposure Change (In $ millions/Actual) (CER) (As % of CER sales) (In $ millions) Fourth quarter 2020 U.S. dollar 276.9 276.9 49% 0.0 Euro 143.8 133.5 24% 10.3 British pound 19.9 19.4 4% 0.5 Japanese yen 17.2 16.5 3% 0.7 Other currencies 11

26. Slide 26: 2020: Quarterly and full-year income statement summary

    2020: Quarterly and full-year income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2020 Q2 2020 Q3 2020 Q4 2020 FY 2020 Net sales 372.1 443.3 483.8 571.2 1,870.3 Net sales (CER) 379.0 452.4 481.3 560.7 1,873.4 Gross profit 243.5 295.0 320.8 373.4 1,232.7 Gross p

27. Slide 27: 2019: Quarterly and full-year income statement summary

    2019: Quarterly and full-year income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2019 Q2 2019 Q3 2019 Q4 2019 FY 2019 Net sales 348.7 381.6 382.7 413.5 1,526.4 Gross profit 224.8 245.9 254.9 279.6 1,005.3 Gross profit margin 64% 64% 67% 68% 66% Adjusted gross

28. Slide 28: Consolidated Balance Sheets

    Consolidated Balance Sheets December 31, December 31, December 31, December 31, (In $ thousands, except par value) 2020 2019 (In $ thousands, except par value) 2020 2019 Assets (unaudited) Liabilities and Equity (unaudited) Current liabilities: Current assets: Current portion of long-term debt 42,53

29. Slide 29: Consolidated Statements of Cash Flows (unaudited)

    Consolidated Statements of Cash Flows (unaudited) Twelve months ended Twelve months ended December 31, December 31, December 31, December 31, (In $ thousands) 2020 2019 (In $ thousands) 2020 2019 Cash flows from operating activities: Cash flows from financing activities: Net income (loss) 359,188 (4

30. Slide 30: Employees as of December 31, 2020

    Employees as of December 31, 2020 Europe / Asia Pacific / Total Total Americas Middle East / Africa Japan / ROW Q4 2020 Q4 2019 Change Production 392 1,030 144 1,566 1,164 35% R&D 210 642 50 902 953 -5% Sales 575 825 792 2,192 2,070 6% Marketing 71 177 82 330 309 7% Administration 80 385 155 620 600

31. Slide 31: Your contacts

    Your contacts John Gilardi Vice President Calendar Corporate Communications and IR Phone: +49 2103 29 11711 Q1 2021 results May 2021 +1 240 686 2222 Mobile: +49 152 018 11711 Annual General Meeting June 2021 E-mail: john.gilardi@qiagen.com Q2 2021 results July 2021 Phoebe Loh Share information Direc

Qiagen — Exane BNPP DILS CEO Conference 2021 on 6ix